Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients

Journal of Human Hypertension

Volumn 25, Issue 3, 2011, Pages 172-177

  Jiang, S ^a,b   Yu, Y ^b   Venners, S A ^c   Zhang, Y ^b   Xing, H ^b   Wang, X ^e   Xu, X ^b,d  

^a ANHUI UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c SIMON FRASER UNIVERSITY   (Canada)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Benazepril; homocysteine; MS; MTHFR; SNP

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BENAZEPRIL; DNA; METHIONINE SYNTHASE;

ADULT; ARTICLE; CHINESE; DIASTOLIC BLOOD PRESSURE; DNA EXTRACTION; DRUG EFFICACY; ENZYME MODIFICATION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 79951671454     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.50     Document Type: Article

References (39)

1. Balfour JA, Goa KL. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 1991; 42: 511-539. (Pubitemid 21920773)
2. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenete-trahydrofolate reductase [Letter]. Nat Genet 1995; 10: 111-113.
3. Chen LH, Liu M-L, Hwang H-Y, Chen L-S, Korenberg J, Shane B. Human methionine synthase cDNA cloning, gene localization and expression. J Biol Chem 1997; 272: 3628-3634.
4. Chen J, Stampfer MJ, Ma J, Selhub J, Malinow MR, Hennekens CH et al. Influence of a methionine synthase (D919G) polymorphism on plasma homocys-teine and folate levels and relation to risk of myocar-dial infarction. Atherosclerosis 2001; 154: 667-672. (Pubitemid 32232164)
5. Feix A, Fritsche-Polanz R, Kletzmayr J, Vychytil A, Horl WH, Sunder-Plassmann G et al. Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homo-cysteine plasma levels. Am J Kidney Dis 2001; 38(5): 956-964. (Pubitemid 33022172)
6. Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Humphries SE. Gene-environment and gene/gene interaction in the determination of plasma homocys-teine levels in healthy middle-aged men. Thromb Haemost 2001; 85: 67-74. (Pubitemid 32050945)
7. Jain S, Ram H, Kumari S, Khullar M. Plasma homo-cysteine levels in Indian patients with essential hypertension and their siblings. Ren Fail 2003; 25(2): 195-201. (Pubitemid 36529662)
8. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96: 1745-1749. (Pubitemid 27400728)
9. Bortolotto LA, Safar ME, Billaud E, Lacroix C, Asmar R, London GM et al. Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension 1999; 34: 837-842. (Pubitemid 29501309)
10. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocys-teine Study. JAMA 1995; 274: 1526-1533.
11. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002; 156: 1105-1113. (Pubitemid 35453681)
12. Qian X, Lu Z, Tan M, Liu H, Lu D. A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur J Hum Genet 2007; 15(12): 1239-1245. (Pubitemid 350143180)
13. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009; 41: 666-676.
14. Li D, Xing H, Hao K, Peng S, Wu D, Guang W et al. Hypertensive patients from two rural Chinese counties respond differently to benazepril: the Anhui Hypertension Health Care Study. Ann Epidemiol 2004; 14(2): 123-128. (Pubitemid 38221170)
15. Buffone GJ, Darlington GJ. Isolation of DNA from biological specimens without extraction with phenol. Clin Chem 1985; 31: 164-165.
16. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996; 5: 1867-1874. (Pubitemid 26413628)
17. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130.
18. Pinto X, Vilaseca MA, Garcia-Giralt N, Ferrer I, Pala M, Meco JF et al. Homocysteine Study Group. Homo-cysteine and the MTHFR 677C-4T allele in premature coronary artery disease. Case control and family studies. Eur J Clin Invest 2001; 31(1): 24-30. (Pubitemid 32151118)
19. Tsai MY, Bignell M, Yang F, Welge BG, Graham KJ, Hanson NQ. Polygenic influence on plasma homo-cysteine: association of two prevalent mutations, the 844ins68 of cystathionine b-synthase and A2756G of methionine synthase, with lowered plasma homocys-teine levels. Atherosclerosis 2000; 149: 131-137. (Pubitemid 30125981)
20. Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 1996; 58: 17-20.
21. Wang XL, Duarte N, Cai H, Adachi T, Sim AS, Cranney G et al. Relationship between total plasma homocys-teine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis 1999; 146: 133-140. (Pubitemid 29371871)
22. Zhao F, Li JP, Wang SY, Guan DM, Ge JB, Hu J et al. The effect of baseline homocysteine level on the efficacy of enalapril maleate and folic acid tablet in lowering blood pressure and plasma homocysteine. Zhonghua Yi Xue Za Zhi 2008; 88(42): 2957-2961.
23. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. JAMA 1995; 274: 1049-1057.
24. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-1082.
25. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. Homocysteine and essential hypertension. J Clin Pharmacol 2003; 43: 1299-1306. (Pubitemid 37433302)
26. van Dijk RA, Rauwerda JA, Steyn M, Twisk JW, Stehouwer CD. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001; 21: 2072-2079. (Pubitemid 34219764)
27. Jiang S, Hsu YH, Xu X, Xing H, Chen C, Niu Tet al. The C677T polymorphism of the methylenetetrahydrofo-late reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-convert-ing enzyme inhibitor. Thromb Res 2004; 113(6): 361-369. (Pubitemid 38844366)
28. Hoshino J, Nakamura T, Kurashina T, Saito Y, Sumino H, Ono Z et al. Antagonism of ANG II type 1 receptors protects the endothelium during the early stages of renal hypertension in rats. Am J Physiol Regul Integr Comp Physiol 1998; 275: 1950-1957.
29. Griendling KK, Alexander RW. Endothelial control of the cardiovascular system: recent advances. FASEB J 1996; 10: 283-292. (Pubitemid 26079947)
30. Katori M, Majima M. Preventive role of renal kallik-rein-kinin system in the early phase of hypertension and development of new antihypertensive drugs. Adv Pharmacol 1998; 44: 147-224.
31. Ergul A. Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension 2000; 36: 62-67. (Pubitemid 30602153)
32. Schiffrin EL. Endothelin and endothelin antagonists in hypertension. J Hypertens 1998; 16(12 Pt 2): 1891-1895. (Pubitemid 29002365)
33. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
34. Ishigai Y, Mori T, Ikeda T, Fukuzawa A, Shibano T. Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardio-myocytes. Am J Physiol Heart Circ Physiol 1997; 273: 2659-2663.
35. Clozel M. Mechanism of action of angiotensin converting enzyme inhibitors on endothelial function in hypertension. Hypertension 1991; 18(Suppl II): II37-II42.
36. Hoshino J, Sakamaki T, Nakamura T, Kobayashi M, Kato M, Sakamoto H et al. Exaggerated vascular response due to endothelial dysfunction and role of the renin-angiotensin system at early stage of renal hypertension in rats. Circ Res 1994; 74: 130-138.
37. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; 100: 1161-1168. (Pubitemid 29426590)
38. Kitiyakara C, Gonin J, Massy Z, Wilcox CS. Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidate stress and hyperho-mocysteinemia. Curr Opin Nephrol Hypertens 2000; 9: 477-487.
39. Poduri A, Kaur J, Thakur JS, Kumari S, Jain S, Khullar M. Effect of ACE inhibitors and beta-blockers on homocysteine levels in essential hypertension. J Hum Hypertens 2008; 22: 289-294. (Pubitemid 351419497)